For patients already stable on oral aripiprazole or another oral antipsychotic, after the first ABILIFY MAINTENA injection, continue treatment with the antipsychotic for 14 consecutive days. ABILIFY MAINTENA is only to be administered by intramuscular injection by a healthcare professional.
Abilify Maintena contains an atypical antipsychotic for intramuscular injection given once monthly. As a result, patients need to schedule an appointment at a healthcare center elsewhere.Furthermore, patients may feel stigmatized by having the medication administered in an injection, Dr Thase explained.

"There's more of a sense of being in control when you know you can stop your drugs whenever you want to. The US Food and Drug Administration (FDA) has approved a new indication for Abilify Maintena (aripiprazole), making it the first once-monthly, long-acting injectable approved for maintenance monotherapy treatment of The approval was announced by H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd.In a 52-week, phase 3 clinical study, Abilify Maintena delayed the time to recurrence of any mood episode in adult patients experiencing a manic episode at screening, compared with placebo, according to a company press release.“Abilify Maintena provides healthcare professionals (HCPs) a new treatment option for their patients who have established tolerability with oral aripiprazole,” said Joseph Calabrese, MD, director of the Mood Disorders Program at University Hospitals Cleveland Medical Center, and professor of psychiatry at Case Western Reserve University School of Medicine, Cleveland, Ohio.

The intramuscular injections are available for monotherapy in preparations of 300 mg or 400 mg. Maintena did not prevent depressive episodes.
• ABILIFY MAINTENA is the first and only FDA-approved once-monthly* injectable for both schizophrenia and maintenance monotherapy treatment of bipolar I disorder in adults *Establish tolerability with oral aripiprazole before initiating therapy. Reactions have ranged from pruritus/urticaria to anaphylaxis.To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (To report SUSPECTED ADVERSE REACTIONS, contact Otsuka America Pharmaceutical, Inc. at 1-800-438-9927 or FDA at 1-800-FDA-1088 (As circumstances related to the COVID-19 situation continue to unfold, Otsuka and Lundbeck are here to support you.As circumstances related to the COVID-19 situation continue to unfold, Otsuka and Lundbeck are here to support you.For information on accessing medication, injection services, and copay assistance, visit Questions for your local Account Manager? Abilify, known by the generic name aripiprazole, is an atypical antipsychotic medication that is approved to treat a number of disorders, including bipolar disorder. Close more info about Abilify Maintena Gains New Bipolar I Disorder Indication Close more info about Abilify Maintena Gains New Bipolar I Disorder Indication

“Receiving Abilify Maintena each month as prescribed and administered by a HCP, provides patients an opportunity to be free from taking their daily antipsychotic for bipolar I disorder.”An oral antipsychotic must be taken concurrently for 14 days after the first injection, Dr. Calabrese said.The double-blind, placebo-controlled, randomized withdrawal trial involved adults aged 18 to 65 years stabilized with Abilify Maintena prior to randomization. Please login or register first to view this content.Copyright © 2020 Haymarket Media, Inc. All Rights ReservedRegister now at no charge to access unlimited daily drug news, medication safety alerts & recalls, and industry-supported drug information & education.Please login or register first to view this content. It's specifically used to treat manic and mixed episodes in bipolar disorder, either alone or in combination with other anti-manic medications. 3, however there are inconsistent results when it has been studied in conjunction with a mood stabilizer (e.g. "Given how important adherence is in preventing the risk of relapse, we should be open to the possibility of improvement with long-acting treatments available to us," Dr Thase said.Copyright © 2020 by RxList Inc. RxList does not provide medical advice, diagnosis or treatment.

The purpose of this study was to evaluate the safety, tolerability, and efficacy of AOM 400 as long-term maintenance treatment for BP-I. It is in the treatment of bipolar depression where the evidence is weak and contradictory. ABILIFY Injection is intended for intramuscular use only.